Skye Bioscience

Skye Bioscience, Inc. is a biopharmaceutical firm focused on the discovery, development, and commercialization of cannabinoid-based therapeutics, primarily targeting various ophthalmic conditions. The company's leading drug candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. In addition, Skye Bioscience is developing SBI-200, which is in preclinical stages, to manage and treat a spectrum of eye diseases such as uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. The company, originally named Emerald Bioscience, Inc., rebranded to Skye Bioscience, Inc. in January 2021. Founded in 2012, its headquarters are situated in San Diego, California.